SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Aesthetic Medical International Holdings Group Ltd. – ‘20-F/A’ for 12/31/22

On:  Friday, 9/22/23, at 4:01pm ET   ·   For:  12/31/22   ·   Accession #:  1104659-23-103170   ·   File #:  1-39088

Previous ‘20-F’:  ‘20-F’ on 4/21/23 for 12/31/22   ·   Next & Latest:  ‘20-F’ on 4/25/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/22/23  Aesthetic Medical Int’l Hold… Ltd 20-F/A     12/31/22   17:380K                                   Toppan Merrill/FA

Amendment to Annual or Annual-Transition Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F/A      Amendment to Annual or Annual-Transition Report by  HTML     57K 
                a Foreign Non-Canadian Issuer                                    
 4: EX-13.1     Annual or Quarterly Report to Security Holders      HTML      9K 
 5: EX-13.2     Annual or Quarterly Report to Security Holders      HTML      9K 
 2: EX-12.1     Statement re: the Computation of Ratios             HTML     13K 
 3: EX-12.2     Statement re: the Computation of Ratios             HTML     13K 
 6: EX-15.3     Letter re: Unaudited Interim Financial Info         HTML     16K 
 7: EX-15.4     Letter re: Unaudited Interim Financial Info         HTML     11K 
12: R1          Cover                                               HTML     92K 
15: XML         IDEA XML File -- Filing Summary                      XML     13K 
13: XML         XBRL Instance -- aih2326724d1_20fa_htm               XML     31K 
14: EXCEL       IDEA Workbook of Financial Report Info              XLSX      9K 
 9: EX-101.DEF  XBRL Definitions -- aih-20221231_def                 XML     85K 
10: EX-101.LAB  XBRL Labels -- aih-20221231_lab                      XML    115K 
11: EX-101.PRE  XBRL Presentations -- aih-20221231_pre               XML     81K 
 8: EX-101.SCH  XBRL Schema -- aih-20221231                          XSD     14K 
16: JSON        XBRL Instance as JSON Data -- MetaLinks               30±    40K 
17: ZIP         XBRL Zipped Folder -- 0001104659-23-103170-xbrl      Zip     40K 


‘20-F/A’   —   Amendment to Annual or Annual-Transition Report by a Foreign Non-Canadian Issuer


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX: 
 i 0001757143  i false  i --12-31  i 2022  i FY  i Aesthetic Medical International Holdings Group Ltd  i true  i NASDAQ 0001757143 2022-01-01 2022-12-31 0001757143 dei:BusinessContactMember 2022-01-01 2022-12-31 0001757143 aih:AmericanDepositarySharesMember 2022-01-01 2022-12-31 0001757143 ifrs-full:OrdinarySharesMember 2022-01-01 2022-12-31 0001757143 2022-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM  i 20-F/A

 

 i ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

 i x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended  i December 31, 2022

 

OR

 

 i ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

 i ¨ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of event requiring this shell company report for the transition period from ____________to ____________

 

Commission file number:  i 001-39088

 

Aesthetic Medical International Holdings Group Limited

(Exact Name of Registrant as Specified in its Charter)

 

N/A

(Translation of Registrant’s Name into English)

 

 i Cayman Islands

(Jurisdiction of Incorporation or Organization)

 

 i 1122 Nanshan Boulevard

 i Nanshan District i Shenzhen

 i Guangdong Province i China  i 518052

(Address of principal executive offices)

 

 i Wu Guanhua, Chief Financial Officer

E-mail:  i toby@pengai.com.cn

 i 1122 Nanshan Boulevard

 i Nanshan District i Shenzhen

 i Guangdong Province i China  i 518052

Telephone: + i 86 ( i 755 i 2665 0533

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol  Name of Each Exchange on Which
Registered

 i American depositary shares, each representing three ordinary shares

 

 i Ordinary shares, par value US$0.001 per share*

 i AIH

 

true

 i NASDAQ Stock Market LLC

 

NASDAQ

 

 

*            Not for trading, but only in connection with the listing of the American depositary shares on The NASDAQ Stock Market LLC.

 

Securities registered or to be registered pursuant to Section 12(g) of the Act:

 

None

(Title of Class)

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

 

None

(Title of Class)

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:

 

As of December 31, 2022, the issuer had  i 94,044,740 shares outstanding.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨  i No x

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ¨  i No x

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  i Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  i Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer ¨
 i Non-accelerated filer x Emerging growth company  i x

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  i ¨

 

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  i ¨

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ¨

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

U.S. GAAP ¨  i International Financial Reporting Standards as issued by the International Accounting Standards Board x Other ¨

 

* If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ¨Item 18 ¨

 

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  i ¨ No x

 

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ¨ No ¨

 

Auditor name:  i Union Power HK CPA Limited Location:  i Hong Kong, China Auditor Firm ID:  i 3004

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Amendment No.1 on Form 20-F (“Form 20-F/A”) is being filed to amend the Annual Report on Form 20-F for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on April 21, 2023 (the “Original Form 20-F”) of Aesthetic Medical International Holdings Group Limited (the “Company”, “we”, “us”, “our” or our company). This Form 20-F/A is being filed to add the following paragraphs as “ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS”:

 


ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

(a).          Please see the Supplemental Submission Pursuant to Item 16I(a) of Form 20-F, which has been furnished as Exhibit 15.3 to this Form 20-F/A.

 

(b).          On June 14, 2022, we were conclusively identified by the SEC as a “Commission-Identified Issuer” under the HFCAA following the filing of our annual report on Form 20-F for the fiscal year ended December 31, 2021. Our auditor, a registered public accounting firm that the PCAOB was unable to inspect or investigate completely in 2021, issued an audit report for our fiscal year ended December 31, 2021. On December 15, 2022, the PCAOB issued a report that vacated its December 16, 2021 determination and removed mainland China and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. As a result, we do not expect to be identified as a “Commission-Identified Issuer” under the HFCAA for the fiscal year ended December 31, 2022 after we file our annual report on Form 20-F for such fiscal year.

 

 

 

 

As of the date of the Original Form 20-F:

 

(i)MY Universe (HK) Limited (“MYU”) held 36,402,570 ordinary shares of our company, representing 27.9% of the total number of ordinary shares issued and outstanding as of the same date. MYU is a company incorporated in Hong Kong, which is wholly owned by Hainan Oriental Jiechuang Investment Partnership (“Jiechuang”). Jiechuang is a limited partnership incorporated in Hainan Province, China, which has two general partners, namely, Shenzhen Lafang Investment Management Co., Ltd. (“LaFang Investment”) and Shenzhen Venture Capital M&A Fund Management (Shenzhen) Co., Ltd. (“SVC”). SVC owned 11.72% of equity interest in Jiechuang. The majority of the equity interest of SVC is collectively and beneficially owned by several government-owned entities of the PRC. Other than the ordinary shares of our company owned by MYU, none of the shares of our company or our consolidated foreign operating entities (as set out in Exhibit 15.4 filed herein) is owned by governmental entities in the Cayman Islands, the British Virgin Islands, Singapore, the United States, Hong Kong, or mainland China.

 

(ii)none of the governmental entities in Hong Kong or mainland China have a controlling financial interest in us or any of our consolidated foreign operating entities;

 

(iii)none of the members of our board of directors or the board of directors of our consolidated foreign operating entities is an official of the Chinese Communist Party; and

 

(iv)the currently effective memorandum and articles of association of our company or equivalent organizing documents of our consolidated foreign operating entities do not contain any charter of the Chinese Communist Party, including the text of any such articles or organizing documents.

 

Item 19. EXHIBITS

 

EXHIBIT INDEX

 

Exhibit   Exhibit title
12.1   Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
12.2   Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
13.1   Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
13.2   Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
15.3   Supplemental Submission Pursuant to Item 16I(a) of Form 20-F.
     
15.4   List of consolidated foreign operating entities of the registrant.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

 

  Aesthetic Medical International Holdings Group Limited
     
  By: /s/ Zhang Chen
  Name: Zhang Chen
  Title: Chairman
     
  Dated: September 22, 2023

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘20-F/A’ Filing    Date    Other Filings
Filed on:9/22/23
4/21/2320-F
For Period end:12/31/2220-F
12/15/22
6/14/22
12/31/2120-F,  NT 20-F
12/16/21
4/5/12
 List all Filings 
Top
Filing Submission 0001104659-23-103170   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., May 5, 5:18:54.2am ET